Imaging and response in soft tissue sarcomas

Hematology/Oncology Clinics of North America

Volumn 19, Issue 3, 2005, Pages 471-487

  Schuetze, Scott M ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ANTINEOPLASTIC AGENT; CHOLINE C 11; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; DACARBAZINE; DEOXYFLUOROTHYMIDINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GLUCOSE; IFOSFAMIDE; IMATINIB; MELPHALAN; STEM CELL FACTOR RECEPTOR; THALLIUM 201; TRACER; TUMOR NECROSIS FACTOR ALPHA; TYROSINE C 11; UNCLASSIFIED DRUG; VINCRISTINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CELL VIABILITY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM CANCER; DRUG FATALITY; DRUG SAFETY; EWING SARCOMA; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GLUCOSE TRANSPORT; HAND AMPUTATION; HUMAN; HYPERTHERMIC THERAPY; LIMB PERFUSION; LIMB TUMOR; MYXOSARCOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; RETROPERITONEAL CANCER; REVIEW; SCINTIGRAPHY; SOFT TISSUE SARCOMA; SURGICAL ANATOMY; TISSUE NECROSIS; TREATMENT FAILURE;

GASTROINTESTINAL STROMAL TUMORS; GLUCOSE; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SARCOMA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 20444393142     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2005.03.001     Document Type: Review

References (53)

1. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
2. D.M. Panicek, E.S. Casper, and M.F. Brennan Hemorrhage simulating tumor growth in malignant fibrous histiocytoma at MR imaging Radiology 181 2 1991 398 400
3. F.C. Eilber, G. Rosen, and J. Eckardt Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas J Clin Oncol 19 13 2001 3203 3209
4. P.W. Pisters, D.H. Leung, and J. Woodruff Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities J Clin Oncol 14 5 1996 1679 1689
5. T.F. DeLaney, I.J. Spiro, and H.D. Suit Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas Int J Radiat Oncol Biol Phys 56 4 2003 1117 1127
6. M. Van Glabbeke, J. Verweij, and I. Judson Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Eur J Cancer 38 4 2002 543 549
7. K. Antman, J. Crowley, and S.P. Balcerzak An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas J Clin Oncol 11 7 1993 1276 1285
8. J.H. Edmonson, L.M. Ryan, and R.H. Blum Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas J Clin Oncol 11 7 1993 1269 1275
9. C.M. Pezzi, R.E. Pollock, and H.L. Evans Preoperative chemotherapy for soft-tissue sarcomas of the extremities Ann Surg 211 4 1990 476 481
10. F. Meric, K.R. Hess, and D.G. Varma Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas Cancer 95 5 2002 1120 1126
11. R.D. Issels, S. Abdel-Rahman, and C. Wendtner Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study Eur J Cancer 37 13 2001 1599 1608
12. C.M. Wendtner, S. Abdel-Rahman, and M. Krych Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas J Clin Oncol 20 14 2002 3156 3164
13. K. James, E. Eisenhauer, and M. Christian Measuring response in solid tumors: unidimensional versus bidimensional measurement J Natl Cancer Inst 91 6 1999 523 528
14. L.H. Schwartz, M.S. Ginsberg, and D. DeCorato Evaluation of tumor measurements in oncology: use of film-based and electronic techniques J Clin Oncol 18 10 2000 2179 2184
15. P.W. Pisters, S.R. Patel, and D.G. Varma Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution J Clin Oncol 15 12 1997 3481 3487
16. E.S. Casper, J.J. Gaynor, and L.B. Harrison Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma Cancer 73 6 1994 1644 1651
17. F. O'Sullivan, S. Roy, and J. Eary A statistical measure of tissue heterogeneity with application to 3D PET sarcoma data Biostatistics 4 3 2003 433 448
18. J.F. Eary, F. O'Sullivan, and Y. Powitan Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis Eur J Nucl Med Mol Imaging 29 9 2002 1149 1154
19. D.N. Jones, G.B. McCowage, and H.D. Sostman Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET J Nucl Med 37 9 1996 1438 1444
20. R.J. van Ginkel, H.J. Hoekstra, and J. Pruim FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma J Nucl Med 37 6 1996 984 990
21. J.G. Rajendran, D.C. Wilson, and E.U. Conrad [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression Eur J Nucl Med Mol Imaging 30 5 2003 695 704
22. D.C. Cobben, P.H. Elsinga, and A.J. Suurmeijer Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′- deoxy-L-thymidine Clin Cancer Res 10 5 2004 1685 1690
23. A.F. Shields, D.A. Mankoff, and J.M. Link Carbon-11-thymidine and FDG to measure therapy response J Nucl Med 39 10 1998 1757 1762
24. R.J. van Ginkel, A.C. Kole, and O.E. Nieweg L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer J Nucl Med 40 2 1999 262 267
25. H. Zhang, M. Tian, and N. Oriuchi 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET Nucl Med Commun 24 3 2003 273 279
26. A.L. Folpe, R.H. Lyles, and J.T. Sprouse (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma Clin Cancer Res 6 4 2000 1279 1287
27. J.F. Eary, and D.A. Mankoff Tumor metabolic rates in sarcoma using FDG PET J Nucl Med 39 2 1998 250 254
28. J.F. Eary, and E.U. Conrad Positron emission tomography in grading soft tissue sarcomas Semin Musculoskelet Radiol 3 2 1999 135 138
29. H. Young, R. Baum, and U. Cremerius Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 13 1999 1773 1782
30. S.M. Schuetze, B.P. Rubin, and C. Vernon Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy Cancer 103 2 2005 339 348
31. A.R. Padhani, and J.E. Husband Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies Clin Radiol 56 8 2001 607 620
32. H. Brisse, L. Ollivier, and V. Edeline Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment Pediatr Radiol 34 8 2004 595 605
33. B.D. Fletcher, S.L. Hanna, and D.L. Fairclough Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy Radiology 184 1 1992 243 248
34. W.E. Reddick, S. Wang, and X. Xiong Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma Cancer 91 12 2001 2230 2237
35. K. Nakanishi, N. Araki, and H. Yoshikawa Alveolar soft part sarcoma Eur Radiol 8 5 1998 813 816
36. L.G. Shapeero, D. Vanel, and K.L. Verstraete Fast magnetic resonance imaging with contrast for soft tissue sarcoma viability Clin Orthop 397 2002 212 227
37. C.S. van Rijswijk, M.J. Geirnaerdt, and P.C. Hogendoorn Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results Eur Radiol 13 8 2003 1849 1858
38. D. Vanel, S. Bonvalot, and J.M. Guinebretiere MR imaging in the evaluation of isolated limb perfusion: a prospective study of 18 cases Skeletal Radiol 33 3 2004 150 156
39. P.E. Sijens Phosphorus MR spectroscopy in the treatment of human extremity sarcomas NMR Biomed 11 7 1998 341 353
40. H.D. Sostman, D.M. Prescott, and M.W. Dewhirst MR imaging and spectroscopy for prognostic evaluation in soft-tissue sarcomas Radiology 190 1 1994 269 275
41. C. Kettelhack, M. Wickede, and T. Vogl 31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors Cancer 94 5 2002 1557 1564
42. O.M. Redmond, J.P. Stack, and N.G. O'Connor 31P MRS as an early prognostic indicator of patient response to chemotherapy Magn Reson Med 25 1 1992 30 44
43. J.A. Koutcher, D. Ballon, and M. Graham 31P NMR spectra of extremity sarcomas: diversity of metabolic profiles and changes in response to chemotherapy Magn Reson Med 16 1 1990 19 34
44. P.E. Sijens, A.M. Eggermont, and P.V. van Dijk 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion NMR Biomed 8 5 1995 215 224
45. P.F. Choong, I. Nizam, and S.Y. Ngan Thallium-201 scintigraphy-a predictor of tumour necrosis in soft tissue sarcoma following preoperative radiotherapy? Eur J Surg Oncol 29 10 2003 908 915
46. L.R. Menendez, B.M. Fideler, and J. Mirra Thallium-201 scanning for the evaluation of osteosarcoma and soft-tissue sarcoma. A study of the evaluation and predictability of the histological response to chemotherapy J Bone Joint Surg Am 75 4 1993 526 531
47. G.D. Demetri, M. von Mehren, and C.D. Blanke Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 7 2002 472 480
48. J. Verweij, P.G. Casali, and J. Zalcberg Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 9440 2004 1127 1134
49. H. Joensuu, P.J. Roberts, and M. Sarlomo-Rikala Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 14 2001 1052 1056
50. I. Gayed, T. Vu, and R. Iyer The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors J Nucl Med 45 1 2004 17 21
51. G.W. Goerres, R. Stupp, and G. Barghouth The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate Eur J Nucl Med Mol Imaging 32 2 2005 153 162
52. P.L. Jager, J.A. Gietema, and W.T. van der Graaf Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET Nucl Med Commun 25 5 2004 433 438
53. S. Stroobants, J. Goeminne, and M. Seegers 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) Eur J Cancer 39 14 2003 2012 2020